
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay Ltd's proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology has received positive regulatory recognition, exemplified by the FDA approval of the ProlivRx at-home neuromodulation device, marking a significant milestone in expanding the treatment landscape for mental health disorders. The company is experiencing an expansion in forward earnings multiples, with the financial evaluation reflecting an intrinsic value of $100 million associated with its strategic investment in Neurolief, indicating robust growth potential. Additionally, the ongoing clinical trials and increasing acceptance of pay-per-use models signal a favorable market trend and potential for increased adoption of Deep TMS therapies among a broader range of medical specialists.
Bears say
The financial outlook for BrainsWay Ltd appears negative due to several significant risks that could impact its growth trajectory. These risks include the slower-than-anticipated adoption of its Deep TMS systems, challenges in securing reimbursement and expanding market access, and hurdles in advancing its technology into new indications. Furthermore, there is a potential for long-term dilution risk, which may adversely affect shareholder value and overall financial stability.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares